Top Qs
Timeline
Chat
Perspective
HU6
Chemical compound From Wikipedia, the free encyclopedia
Remove ads
HU6 is a prodrug of the mitochondrial uncoupler 2,4-dinitrophenol (DNP) that is intended to "minimize the rapid absorption and high peak blood concentrations of DNP to provide a wider therapeutic index and improve safety."[1] Developed by Rivus Pharmaceuticals, the drug is tested to reduce weight and liver fat in humans with risk factors for metabolic dysfunction-associated steatohepatitis. In a phase 2a trial, the higher dosage levels reduced liver fat on average by more than 30 percent and also reduced body weight significantly.[2][3] A phase 2b trial was launched in late 2023.[4] A phase 2b trial in patients with metabolic dysfunction-associated steatohepatitis was subsequently initiated.[5] Data from this study are expected to be reported in 2025. Additionally, a phase 2a study was performed in patients suffering from heart failure with preserved ejection fraction, a disease that is mediated by visceral fat and obesity. The study achieved the primary endpoint of weight loss, as well as a number of secondary endpoints.[6]
Remove ads
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads